{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:17Z","timestamp":1794029057782,"version":"4.8.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002613","name":"Ulsan National Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["402967\/2025-9"],"award-info":[{"award-number":["402967\/2025-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119295","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:02:31Z","timestamp":1774954951000},"page":"119295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Leukemic stem cells as drivers of therapeutic resistance in acute myeloid leukemia"],"prefix":"10.1016","volume":"198","author":[{"given":"Suellen L.R.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela A. da C.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o V.B.","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-2063","authenticated-orcid":false,"given":"Daniel P.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2026.119295_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary management of acute myeloid leukemia: a review","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2026.119295_bib3","volume":"2026","author":"American Cancer Society","year":"2026"},{"key":"10.1016\/j.biopha.2026.119295_bib4","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Acute Myeloid Leukemia (AML). Accessed at \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009 on february 27, 2026."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473646","article-title":"Moving away from standard induction in newly diagnosed acute myeloid leukemia","volume":"45","author":"Okoniewski","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib7","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119295_bib8","article-title":"AML and the art of remission maintenance","volume":"49","author":"Lima","year":"2021","journal-title":"Blood Rev."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119295_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737140.2024.2306164","article-title":"Considerations regarding maintenance therapy for acute myeloid leukemia in remission","volume":"24","author":"Schiller","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.biopha.2026.119295_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103277","article-title":"Cell signaling pathways as molecular targets to eliminate AML stem cells","volume":"160","author":"Rodrigues","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12015-021-10308-6","article-title":"Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications","volume":"18","author":"Long","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biopha.2026.119295_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102692","article-title":"Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells","volume":"62","author":"Costa","year":"2023","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib15","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41375-021-01295-1","article-title":"Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq","volume":"35","author":"Saygin","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2643-3230.BCD-24-0235","article-title":"The crossroads of clonal evolution, differentiation hierarchy, and ontogeny in leukemia development","volume":"6","author":"Sturgeon","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"5892","key":"10.1016\/j.biopha.2026.119295_bib17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.1155998","article-title":"Control of the reversibility of cellular quiescence by the transcriptional repressor HES1","volume":"321","author":"Sang","year":"2008","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.biopha.2026.119295_bib18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41416-023-02401-z","article-title":"A cell cycle centric view of tumour dormancy","volume":"129","author":"Weston","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119295_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4252\/wjsc.v11.i8.476","article-title":"Bone marrow microenvironment: The guardian of leukemia stem cells","volume":"11","author":"Houshmand","year":"2019","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.biopha.2026.119295_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment mechanisms in acute myeloid leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"5973","key":"10.1016\/j.biopha.2026.119295_bib21","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1186624","article-title":"The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.gendis.2023.01.008","article-title":"Signaling pathways governing the behaviors of leukemia stem cells","volume":"11","author":"Azizidoost","year":"2023","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3324\/haematol.2020.266155","article-title":"Targeting Wnt signaling in acute myeloid leukemia stem cells","volume":"107","author":"Pepe","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.stem.2012.09.001","article-title":"Attenuation of miR-126 activity expands HSC in vivo without exhaustion","volume":"11","author":"Lechman","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib26","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-13-1733","article-title":"Attenuation of microRNA-126 expression that drives CD34+38- stem\/progenitor cells in acute myeloid leukemia leads to tumor eradication","volume":"74","author":"de Leeuw","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41467-023-36969-0","article-title":"Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia","volume":"14","author":"Naldini","year":"2023","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.biopha.2026.119295_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12967-020-02384-y","article-title":"WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target","volume":"18","author":"Zhou","year":"2020","journal-title":"J. Transl. Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41467-020-14590-9","article-title":"FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML","volume":"11","author":"Sheng","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100146","article-title":"How to drug a leukemic stem cell: deciphering heterogeneity for better specificity","volume":"2","author":"Worker","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.exphem.2007.11.014","article-title":"MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia","volume":"36","author":"Ho","year":"2008","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-007-0269-7","article-title":"CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age","volume":"86","author":"van den Heuvel-Eibrink","year":"2007","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.critrevonc.2007.02.003","article-title":"ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance","volume":"62","author":"de Jonge-Peeters","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib38","first-page":"6671","article-title":"Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib39","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1038\/s41467-023-41229-2","article-title":"ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia","volume":"14","author":"Ebner","year":"2023","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.biopha.2026.119295_bib40","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.7150\/jca.52641","article-title":"Suppression of aberrant activation Of NF-\u03baB pathway in drug-resistant leukemia stem cells contributes to parthenolide-potentiated reversal of drug resistance in leukemia","volume":"12","author":"Yi","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2026.119295_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","article-title":"Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells","volume":"102","author":"Walter","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/ijlh.13241","article-title":"P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: biological and prognosis implications","volume":"42","author":"da Silveira J\u00fanior","year":"2020","journal-title":"Int J. Lab Hematol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib44","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ajh.24084","article-title":"ABCG2 overexpression in patients with acute myeloid leukemia: impact on stem cell transplantation outcome","volume":"90","author":"Damiani","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ejh.12915","article-title":"ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML","volume":"99","author":"Tiribelli","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib46","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00277-020-04163-7","article-title":"Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia","volume":"99","author":"Kunadt","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2026.119295_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.leukres.2017.09.014","article-title":"Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo","volume":"62","author":"Bouvy","year":"2017","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018372","article-title":"SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes","volume":"6","author":"Jeong","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.biopha.2026.119295_bib49","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/bph.12431","article-title":"Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway","volume":"171","author":"Roy","year":"2014","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib53","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119295_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib55","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ncb2488","article-title":"Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration","volume":"14","author":"Perciavalle","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119295_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-026-02883-9","article-title":"A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia","author":"Chakraborty","year":"2026","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib57","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A Novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119295_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115738","article-title":"BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells","volume":"215","author":"Chiou","year":"2023","journal-title":"Biochem Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1878-0261.70130","article-title":"Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia","volume":"20","author":"Saad","year":"2026","journal-title":"Mol. Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119295_bib61","doi-asserted-by":"crossref","first-page":"11037","DOI":"10.1073\/pnas.94.20.11037","article-title":"p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents","volume":"94","author":"Thottassery","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70106","article-title":"TP53-mutated acute myeloid leukemia: unanswered questions","volume":"43","author":"Bruzzese","year":"2025","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib63","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: mechanisms and Superior Antileukemic Efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.biopha.2026.119295_bib64","first-page":"2399","article-title":"Autophagy, a key mechanism of oncogenesis and resistance in leukemia","volume":"136","author":"Auberger","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.biopha.2026.119295_bib65","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.3390\/cancers12113461","article-title":"Challenges and therapeutic opportunities of autophagy in cancer therapy","volume":"12","author":"Silva","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119295_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2015.8","article-title":"Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia","volume":"1","author":"Watson","year":"2015","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094374","article-title":"Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death","volume":"9","author":"Bosnjak","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-022-01262-y","article-title":"The dual role of autophagy in acute myeloid leukemia","volume":"15","author":"Seo","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib69","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41375-018-0015-2","article-title":"miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding","volume":"32","author":"Peng","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0145-2126(99)00158-7","article-title":"Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia","volume":"24","author":"Guo","year":"2000","journal-title":"Leuk. Res"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib71","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/leu.2016.350","article-title":"p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status","volume":"31","author":"Quint\u00e1s-Cardama","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib72","article-title":"Ribosomal protein L5 induces cellular senescence via p53-p21-pRb pathway to mediate relapse of acute myeloid leukemia","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib73","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1878-0261.13544","article-title":"A guide to epigenetics in leukaemia stem cells","volume":"17","author":"Agrawal-Singh","year":"2023","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib74","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","article-title":"Epigenetic regulation of cancer stemness","volume":"10","author":"Galassi","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2026.119295_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1744018","article-title":"The role of epigenetic modifications in hematological cancers","volume":"16","author":"Ilic","year":"2026","journal-title":"Front Oncol."},{"issue":"7680","key":"10.1016\/j.biopha.2026.119295_bib76","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature24294","article-title":"BCAT1 restricts \u03b1KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation","volume":"551","author":"Raffel","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib77","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib79","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2004-05-1902","article-title":"Internal tandem duplications of the FLT3 gene are present in leukemia stem cells","volume":"106","author":"Levis","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.biopha.2026.119295_bib80","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2026.119295_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104424","article-title":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","volume":"201","author":"Ruglioni","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib82","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12935-025-03763-5","article-title":"Long noncoding RNAs in acute myeloid leukemia: biomarkers, prognostic indicators, and treatment potential","volume":"25","author":"Farajzadeh","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41420-024-01832-8","article-title":"Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer","volume":"10","author":"Xia","year":"2024","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib84","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12943-025-02415-6","article-title":"MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy","volume":"24","author":"Bitaraf","year":"2025","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib85","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.cell.2007.05.022","article-title":"Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs","volume":"129","author":"Rinn","year":"2007","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib86","first-page":"3044","article-title":"Overexpression of LncRNA-HOTAIR promotes chemoresistance in acute leukemia cells","volume":"13","author":"Li","year":"2020","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2026.119295_bib87","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2018.08.005","article-title":"Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15","volume":"67","author":"Gao","year":"2018","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib89","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13287-025-04304-7","article-title":"Mitochondrial quality control in hematopoietic stem cells: mechanisms, implications, and therapeutic opportunities","volume":"16","author":"Liao","year":"2025","journal-title":"Stem Cell Res Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib90","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12185-024-03789-x","article-title":"Metabolic dependencies of acute myeloid leukemia stem cells","volume":"120","author":"Shi","year":"2024","journal-title":"Int J. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib91","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.stem.2011.02.006","article-title":"Targeting HIF1\u03b1 eliminates cancer stem cells in hematological malignancies","volume":"8","author":"Wang","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2026.119295_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4979474","article-title":"The leukemic stem cell niche: adaptation to \"Hypoxia\" versus oncogene addiction","volume":"2017","author":"Cheloni","year":"2017","journal-title":"Stem Cells Int"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib94","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00432-022-03957-8","article-title":"CD36: an emerging therapeutic target for cancer and its molecular mechanisms","volume":"148","author":"Ruan","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119295_bib95","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00018-019-03031-6","article-title":"Role of bone marrow adipocytes in leukemia and chemotherapy challenges","volume":"76","author":"Samimi","year":"2019","journal-title":"Cell Mol. Life Sci."},{"issue":"13","key":"10.1016\/j.biopha.2026.119295_bib96","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood.2019003654","article-title":"Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells","volume":"136","author":"Raffel","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib97","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjh.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","article-title":"FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress","volume":"128","author":"Tothova","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib99","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.2019898114","article-title":"Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II","volume":"134","author":"Jones","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.stem.2018.05.021","article-title":"AMPK\/FIS1-mediated mitophagy is required for self-renewal of human AML stem cells","volume":"23","author":"Pei","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.stem.2018.05.026","article-title":"Mitochondrial shapeshifting impacts AML stemness and differentiation","volume":"23","author":"Schimmer","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","article-title":"Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy","volume":"128","author":"Moschoi","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.biopha.2026.119295_bib103","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/bloodadvances.2020003661","article-title":"Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition","volume":"5","author":"Saito","year":"2021","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.biopha.2026.119295_bib104","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.18632\/oncotarget.7964","article-title":"Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia","volume":"7","author":"Takam Kamga","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2026.119295_bib105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.18292","article-title":"Mesenchymal stroma\/stem cells: Haematologists' friend or foe?","volume":"199","author":"Nachmias","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2026.119295_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104743","article-title":"Extracellular vesicles in acute myeloid leukemia: the role in disease pathogenesis, potential biomarker, and application in clinical settings","volume":"211","author":"Chatterjee","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119295_bib107","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib108","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2026.119295_bib109","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ijc.28198","article-title":"IL-1\u03b2 inhibits self-renewal capacity of dormant CD34\u207a\/CD38\u207b acute myelogenous leukemia cells in vitro and in vivo","volume":"133","author":"Yang","year":"2013","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.biopha.2026.119295_bib111","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","article-title":"CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice","volume":"64","author":"Tavor","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib112","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm909","article-title":"Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia","volume":"9","author":"Matsunaga","year":"2003","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib113","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41467-020-15817-5","article-title":"Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance","volume":"11","author":"Barbier","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2026.119295_bib114","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-17-1556","article-title":"Disruption of Wnt\/\u03b2-Catenin exerts antileukemia activity and synergizes with FLT3 Inhibition in FLT3-mutant acute myeloid leukemia","volume":"24","author":"Jiang","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib115","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/bloodadvances.2019000757","article-title":"Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Lee","year":"2020","journal-title":"Blood Adv."},{"issue":"32","key":"10.1016\/j.biopha.2026.119295_bib116","doi-asserted-by":"crossref","first-page":"52269","DOI":"10.18632\/oncotarget.13699","article-title":"The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed\/refractory acute myeloid leukemia: a phase Ib\/II study","volume":"8","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.biopha.2026.119295_bib117","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-10-1102","article-title":"Dual inhibition of PI3K and mTORC1\/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia","volume":"16","author":"Chapuis","year":"2010","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib118","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12032-015-0650-7","article-title":"MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine","volume":"32","author":"Lu","year":"2015","journal-title":"Med Oncol."},{"issue":"39","key":"10.1016\/j.biopha.2026.119295_bib119","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2018.214379","article-title":"Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation","volume":"105","author":"Boutin","year":"2020","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.biopha.2026.119295_bib121","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1182\/bloodadvances.2020001576","article-title":"Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models","volume":"4","author":"Morrish","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib122","first-page":"1930","article-title":"vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells","volume":"10","author":"den Ouden","year":"1996","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib123","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-04-0212","article-title":"Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia","volume":"11","author":"Raaijmakers","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib124","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"issue":"7626","key":"10.1016\/j.biopha.2026.119295_bib125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib126","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2026.119295_bib127","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41401-023-01112-8","article-title":"Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.biopha.2026.119295_bib128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biopha.2015.05.012","article-title":"Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine","volume":"73","author":"Kim","year":"2015","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.282","article-title":"Inhibition of ULK1 promotes the death of leukemia cell in an autophagy irrelevant manner and exerts the antileukemia effect","volume":"11","author":"Yang","year":"2021","journal-title":"Clin. Transl. Med"},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib130","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib131","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.biopha.2026.119295_bib132","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib133","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib134","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J. Pharm. Exp. Ther."},{"issue":"36","key":"10.1016\/j.biopha.2026.119295_bib135","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-human phase I study of iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119295_bib136","article-title":"Novel lysine-specific histone demethylase 1 inhibitor in acute myeloid leukaemia transformed from essential thrombocythaemia","volume":"5","author":"Hodges","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"7954","key":"10.1016\/j.biopha.2026.119295_bib137","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2026.119295_bib138","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib139","first-page":"1278","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","volume":"110","author":"Hogeling","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biopha.2026.119295_bib141","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib142","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib143","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.biopha.2026.119295_bib144","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib145","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"JR. An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.biopha.2026.119295_bib146","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"Skrti\u0107","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib147","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1172\/JCI38942","article-title":"Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction","volume":"120","author":"Samudio","year":"2010","journal-title":"J. Clin. Invest"},{"issue":"13","key":"10.1016\/j.biopha.2026.119295_bib148","doi-asserted-by":"crossref","first-page":"8348","DOI":"10.1074\/jbc.M114.618769","article-title":"Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine","volume":"290","author":"St\u00e4ubert","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib149","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib150","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115203","article-title":"Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia","volume":"14","author":"So","year":"2022","journal-title":"EMBO Mol. Med"},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib151","first-page":"2070","article-title":"Antiproliferative effects of L-asparaginase in acute myeloid leukemia","volume":"20","author":"Chen","year":"2020","journal-title":"Exp. Ther. Med"},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119295_bib152","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib153","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41375-023-02117-2","article-title":"Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia","volume":"38","author":"Akiyama","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib154","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/cancers17091509","article-title":"Magrolimab therapy in conjunction with conventional chemotherapeutics slows disease progression in pediatric acute myeloid leukemia patient-derived xenograft models","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.biopha.2026.119295_bib155","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib156","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib157","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2026.119295_bib158","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med"},{"issue":"17","key":"10.1016\/j.biopha.2026.119295_bib159","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119295_bib160","article-title":"FEV Maintains Homing and Expansion by Activating ITGA4 Transcription in Primary and Relapsed AML","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib161","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119295_bib162","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ncomms1776","article-title":"CYLD negatively regulates transforming growth factor-\u03b2-signalling via deubiquitinating Akt","volume":"3","author":"Lim","year":"2012","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.biopha.2026.119295_bib163","doi-asserted-by":"crossref","first-page":"15495","DOI":"10.1074\/jbc.M113.545194","article-title":"The transcription factor GLI1 interacts with SMAD proteins to modulate transforming growth factor \u03b2-induced gene expression in a p300\/CREB-binding protein-associated factor (PCAF)-dependent manner","volume":"289","author":"Nye","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib164","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cac2.12235","article-title":"Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells","volume":"41","author":"Silva","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41419-025-07983-5","article-title":"Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors","volume":"16","author":"Neves","year":"2025","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib166","article-title":"Translational drugs targeting cancer stem cells in triple-negative breast cancer","volume":"33","author":"Oliveira","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib167","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119295_bib168","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2018.08.014","article-title":"Prospective isolation and characterization of genetically and functionally distinct AML subclones","volume":"34","author":"de Boer","year":"2018","journal-title":"Cancer Cell"},{"issue":"7765","key":"10.1016\/j.biopha.2026.119295_bib169","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"7679","key":"10.1016\/j.biopha.2026.119295_bib171","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2026.119295_bib172","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med"},{"issue":"7","key":"10.1016\/j.biopha.2026.119295_bib173","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.biopha.2026.119295_bib174","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med"},{"issue":"7664","key":"10.1016\/j.biopha.2026.119295_bib175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119295_bib176","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.12725","article-title":"Advances in understanding the leukaemia microenvironment","volume":"164","author":"Tabe","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib177","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41576-020-0265-5","article-title":"Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics","volume":"22","author":"Nam","year":"2021","journal-title":"Nat. Rev. Genet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib178","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","article-title":"Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization","volume":"22","author":"Baccin","year":"2020","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119295_bib179","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"21","author":"Vyas","year":"2015","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:49:42Z","timestamp":1779245382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":179,"alternative-id":["S0753332226003288"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119295","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukemic stem cells as drivers of therapeutic resistance in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119295"}}